Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Brennan Suggests Exclusivity As Carrot For Finding Drugs To Treat Neglected Diseases

This article was originally published in PharmAsia News

Executive Summary

The opportunity to obtain extended exclusivity would be an effective method to spur research into drugs for diseases of the developing world, AstraZeneca CEO David Brennan suggested during a Nov. 10 press briefing at the 25 International Federation of Pharmaceutical Manufacturers & Associations Assembly in Washington, D.C

You may also be interested in...



Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear

HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups

Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear

HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups

AstraZeneca Outlines Branded Generics Strategy At Emerging Markets Event

LONDON - AstraZeneca plans to broaden its presence across a wide range of developing markets, including small and mid-sized ones, not only to maximize growth but also to smooth out variations in growth rates across countries and regions, top company executives said in a detailed presentation to analysts on March 16

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel